Do antihyperglycemic therapies like liraglutide reduce circulating extracellular vesicle concentrations in individuals with T2D?
Liraglutide significantly reduces circulating extracellular vesicles in T2D patients, suggesting a potential direct vascular benefit and supporting the use of EVs as translational markers of vascular health.
Circulating EVs are elevated in individuals with T2D even in the absence of overt vascular complications, suggesting early endothelial activation. Among antihyperglycemic agents, only liraglutide significantly reduced EV concentrations, pointing to potential direct vascular benefits. This study provides proof-of-concept data supporting EVs as translational markers of vascular health and treatment response in T2D.
Baldassarre et al. (2026) studied this question.